Available to discuss
Support for patients
Our patient information team can help you understand eligibility, connect with a participating site, and answer questions about what participation involves.
For patients
A targeted, oral therapy designed around patients
Zent-001 is an investigational medicine being studied for its potential to give physicians and patients a targeted, non-chemotherapy option — taken as a pill at home, not as an infusion at a clinic.
How it works
Three steps, designed for everyday life
From screening to daily dosing — here's what the journey could look like.
-
01
Biomarker screening
A tissue sample is tested for Cyclin E1 amplification to see if the therapy may be a match.
-
02
Physician discussion
If eligible, your care team reviews whether a Zentia clinical trial is the right next step for you.
-
03
Oral, once-daily dosing
Take a pill at home each day — no infusion visits, with regular check-ins with your study team.
At a glance
What sets it apart
Targeted mechanism · Biomarker-matched · Oral dosing
Why it's different
Designed to interrupt the cancer's survival plan
Cancer cells multiply quickly and make mistakes. They rely on a checkpoint protein called WEE1 to survive. Zent-001 blocks that checkpoint, pushing cancer cells past a point of no return.
Because it's matched to tumor biology and taken orally, the therapy is designed to be more convenient than infusion-based care — fewer trips, fewer disruptions to daily life.
- Not a chemotherapy — a targeted kinase inhibitor
- Oral, once-daily, at-home administration
- Developed with a companion diagnostic
Important considerations
What to discuss with your care team
Zent-001 is investigational and not approved by any health authority. There are risks with any medicine, including side effects. Your care team can help you weigh whether a clinical trial is right for you.— Always discuss your options with your oncologist first
For physicians
Information for healthcare professionals
Physicians can contact medical affairs for trial details, eligibility criteria and how to refer patients to participating sites.